drugset / Trial / NCT04993885
Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies
NaSingle-groupOpen-labelTreatment
Summary
This prospective, open-label, single-center, one-arm clinical trial aims at evaluating the efficacy and safety of avatrombopag in Chinese adult Immune Thrombocytopenia (ITP) patients with autoantibodies fail (due to intolerance or resistance) to eltrombopag or herombopag treatment.
Timeline
- Start
- 2021-09-01
- Primary completion
- 2024-07-31
- Completion
- 2025-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avatrombopag | Small molecule | 20 mg | — |
| Subject | Avatrombopag | Small molecule | 40 mg | — |